Tvardi Therapeutics is trading 5.66% higher at $1.12 in after-hours trading after announcing preclinical data supporting its STAT3 inhibitors in ulcerative colitis.
- TTI-101 reached approximately eight times plasma concentrations in colon tissue.
- In a mouse model, it prevented polyps and adenocarcinomas.
- The after-hours rebound follows a 19.70% regular-session decline on September 24, suggesting investors responded positively to the late announcement.